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The number of people taking statins is set to increase across the globe due to
recent changes in prescription guidelines. For example, half the US population over
40 is now eligible for these drugs, whether they have high serum cholesterol or
not. With such development in policy comes a stronger need for understanding
statins’ myriad of effects. Surprisingly little is known about possible direct actions of
statins on cardiac myocytes, although claims of a direct myocardial toxicity have been
made. Here, we determine the impact of simvastatin administration (40 mg/kg/day)
for 2 weeks in normocholesterolemic rats on cardiac myocyte contractile function and
identify an underlying mechanism. Under basal conditions, statin treatment increased
the time to half (t0.5) relaxation without any effect on the magnitude of shortening,
or the magnitude/kinetics of the [Ca2+]i transient. Enhanced myocyte lusitropy could
be explained by a corresponding increase in phosphorylation of troponin I (TnI) at
Ser23,24. Statin treatment increased expression of eNOS and Ser1177 phosphorylated
eNOS, decreased expression of the NOS-inhibitory proteins caveolins 1 and 3, and
increased (P = 0.06) NO metabolites, consistent with enhanced NO production. It
is well-established that NO stimulates protein kinase G, one of the effectors of TnI
phosphorylation at Ser23,24. Trends for parallel changes in phospho-TnI, phospho-eNOS
and caveolin 1 expression were seen in atrial muscle from patients taking statins. Our
data are consistent with a mechanism whereby chronic statin treatment enhances TnI
phosphorylation and myocyte lusitropy through increased NO bioavailability. We see no
evidence of impaired function with statin treatment; the changes we document at the
level of the cardiac myocyte should facilitate diastolic filling and cardiac performance.
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INTRODUCTION
Statins reduce cardiovascular morbidity and mortality and are widely prescribed to those at risk of
cardiovascular disease, and with established heart disease. A recent reduction in the cardiovascular
risk threshold for statin prescription across the globe means that the number of people taking
statins is set to increase. For example, 13 million more individuals are now eligible for statin
therapy in the US due to recent amendments to ACC/AHA guidelines (Pencina et al., 2014;
Stone et al., 2014). When considered in combination with high-dose statin treatment regimens,
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which are recommended for some patient groups (e.g., Chan
et al., 2007), the importance of fully understanding statins’ effects
on the cardiovascular system is highlighted.
Statins inhibit the enzyme HMG CoA reductase which is
the rate limiting step in cholesterol synthesis. However, it is
well-established that the impact of statins on the cardiovascular
system extends far beyond lowering serum LDL cholesterol.
These ‘pleiotropic’ effects can be beneficial, and include increased
NO bioavailability, anti-oxidant and anti-inflammatory actions
(e.g., see, Davignon, 2004). Much research in this field has focused
on endothelial cells. At the same time, a body of work has
accumulated suggesting concurrent detrimental effects on the
cardiovascular system, mediated through the same HMG CoA
reductase pathway, including the promotion of coronary artery
calcification (see, Okuyama et al., 2015). Surprisingly, little work
has determined direct effects of statins on the cardiac myocyte,
which is the focus of this work. It is essential that the full
impact of statins is understood if prevention and treatment of
cardiovascular disease are to be optimized.
Statins’ pleiotropic effects can be ascribed to depletion of
cholesterol or other products of the HMG CoA reductase
pathway. The latter include the isoprenoids farnesyl
pyrophosphate and geranylgeranyl pyrophosphate which act to
target small and heterotrimeric G proteins to the membrane
(Goldstein and Brown, 1990), and coenzyme Q, a component
of the mitochondrial respiratory chain, whose depletion has
been linked with mitochondrial dysfunction and statin-induced
‘myocardial toxicity’ (Okuyama et al., 2015). For cholesterol-
dependent pleiotropic effects, statins may initially alter tissue
cholesterol levels by limiting de novo cholesterol synthesis. As
cellular cholesterol homeostasis is maintained through sterol
regulatory element (SRE) transcriptional regulation of proteins
involved in the synthesis, uptake and eﬄux of cholesterol
(Reboulleau et al., 2012), changes in tissue cholesterol are
likely to be normalized over time. However, altered expression
of cholesterol homeostatic proteins may have functional
consequences which contribute to statins’ effects.
The influence of statins on NO provides an excellent
illustration of their broad pleiotropic effects. Statins increase
NO bioavailability by a number of isoprenoid-dependent
mechanisms mediated through Rho/Ras which include increased
eNOS expression (via stabilization of eNOS mRNA), enhanced
eNOS activity (via enhanced Akt-dependent phosphorylation)
and reduced NO scavenging (via NADPH oxidase activity) (Laufs
and Liao, 1998; Urbich et al., 2002; Nakagami et al., 2003).
In addition, statin treatment of endothelial cells and cardiac
myocytes (in vitro) decreases expression of caveolin (Feron
et al., 2001; Pugh et al., 2014), a protein which contributes
to cholesterol eﬄux (Ikonen and Parton, 2000) and is under
SRE transcriptional control (Bist et al., 1997). Caveolin is a
key inhibitory regulator of eNOS and this cholesterol-dependent
change in caveolin expression is associated with increased eNOS
activity (Feron et al., 2001; Pugh et al., 2014). Thus isoprenoid-
and cholesterol-dependent effects contribute to statin regulation
of NO bioavailability.
The nature of cholesterol-SRE dependent changes in protein
expression will contribute to a distinct temporal profile of
statin effects. The consequences of short-term treatment of cells
in vitro, a commonly used experimental model, may not reflect
the consequences of chronic treatment. Furthermore, study of
isolated cells removes any paracrine influences present in the
intact heart. Together, this highlights the importance of using
chronic in vivo statin treatment models to understand statins’
effects in the clinical setting.
In the main, work concerned with the direct effect of
statins on the heart has focused on the drug’s ability to limit
remodeling following ischemia-reperfusion (I-R) (Bauersachs
et al., 2001; Verma et al., 2004; Di Napoli et al., 2005; Ye et al.,
2008). These studies have shown that acute statin treatment
in vitro increases Akt activation and NO production in human
ventricular myocytes following hypoxia-reoxygenation protocols
(Verma et al., 2004). In rat, chronic statin treatment in vivo has
been shown to increase myocardial eNOS expression following
(local/global) I-R protocols (Bauersachs et al., 2001; Di Napoli
et al., 2005). Of note, the impact of chronic statin treatment
in vivo on NO pathways in the healthy heart and the impact that
this has on myocyte function have not been studied to date. These
are important considerations as statins are prescribed to those
without established cardiac disease.
Therefore, the aim of the present study was to describe the
impact of chronic statin treatment in vivo on the contractile
function of the ventricular myocyte and identify the mechanisms
responsible. Using a rodent model, our data show no evidence
of myocardial toxicity, but reveal an increase in myocyte
lusitropy (independent of changes in Ca2+ transient decay)
which can be ascribed to phosphorylation of the myofilament
protein troponin I (TnI) and linked to both cholesterol-
dependent and -independent modulation of NO production.
Parallel changes were observed in myocardial samples from
patients taking statins. Such effects at the level of the myocyte
should prove beneficial, promoting diastolic function of the
heart.
MATERIALS AND METHODS
Ethics Statement
Human right atrial samples were obtained from male patients
without a diagnosis of diabetes undergoing coronary artery
by-pass surgery at the Leeds General Infirmary. All patients
gave written informed consent. Data were anonymized. This
study was approved by the Local Research Ethics committee
(01/040, to April 2016) and complies with the principles
outlined in the Declaration of Helsinki. Most atrial muscle
samples (from both control and statin-treated individuals)
contained some fatty tissue which was removed before
processing.
All animal experimentation was approved by the local Animal
Welfare and Ethical Review committee and carried out in
accordance with the Directive 2010/63/EU of the European
Parliament. Adult male Wistar rats were group housed with
12 h light/dark cycles and free access to food and water. For
5 days prior to treatment, animals were acclimatized to reversed
12 h light/dark cycles, so that dosing could be performed at
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the beginning of the dark cycle, to coincide with peak HMG-
CoA reductase activity (Easom and Zammit, 1984). Rats were
administered 40 mg kg−1 simvastatin daily for 14 days by oral
gavage of a 4 mg ml−1 simvastatin saline suspension. Control
animals received equivalent volumes of saline by the same route.
In the rat statins are generally given by oral gavage, to mimic the
situation in the clinic whereby the inactive simvastatin lactone is
hydrolyzed in the liver to the open acid active form of the drug
(Gazzerro et al., 2012), at doses between 10 and 60 mg/kg/day
(e.g., Delbosc et al., 2002; Baytan et al., 2008; Renno et al.,
2015).
Modified Langendorff Procedure
To reduce animal use, a method was deployed which permits
isolation of cardiomyocytes and processing of whole muscle from
the same heart (Macdougall and Calaghan, 2013). Dissociated
myocytes were used in shortening/[Ca2+]i experiments.
Myocardial homogenates were used for sucrose density gradient
fractionation, western blotting and measurement of NO
metabolites.
Shortening and [Ca2+]i
Shortening and [Ca2+]i were measured in fura-2 loaded
myocytes field-stimulated at 0.5 Hz (22–24◦C) in HEPES-based
physiological solution containing (mM): NaCl 137; KCl 5.4;
NaH2PO4 0.33; MgCl2 0.5; HEPES 5; glucose 5.5; CaCl2 1
(pH 7.4) (Cairn Research Optoscan monochromator; Ionoptix
Cell Contractility System). Parameters were measured under
basal conditions and following selective stimulation of β1
or β2 adrenoceptors (ARs). Recordings were taken at the
peak steady-state response (≈5 min) following application of
agonist. Selective β1-AR stimulation was achieved with 100 nM
isoprenaline in the presence of 100 nM ICI 118,551; selective β2-
AR stimulation was achieved with 10 µM zinterol in the presence
of 300 nM CGP20712A.
Western Blotting
Protein expression in myocardial homogenates was measured
by Western blotting as described in (Calaghan et al., 1998).
For unfractionated samples, protein expression was normalized
to GAPDH. For measurement of phosphorylated proteins
(eNOS, TnI, VASP), samples for total and phospho-proteins
were run on separate gels to avoid the interference which
may arise following a stripping protocol. For rodent samples
(for VASP, Ser239 VASP) and all human atrial samples, where
every control and statin sample could not be included on
the same gel, a standard sample (SS) was included on each
gel to allow inter-gel comparisons. For fractionated samples,
equal volumes of fractions were loaded onto SDS-gels and
band density normalized to the sum of the band density in all
fractions.
Sucrose Density Gradient Fractionation
Myocardium was fractionated using detergent-free methods as
described previously (Calaghan et al., 2008). Samples were
homogenized (Ultra-Turrax T8; Ika), then sonicated (Vibra Cell;
Sonics) three times each for 20 s at full power in 500 mM Na2CO3
(pH 11.0) containing 0.5 mM EDTA and 1% protease inhibitor
cocktail (Sigma). Approximately, 2 ml of homogenate was mixed
with an equal volume of 90% sucrose in MES-buffered saline
(25 mM MES, 150 mM NaCl, 2 mM EDTA, pH 6.5) to form a 45%
sucrose solution. A discontinuous sucrose gradient was created
by layering on to this a further 4 ml each of 35 and 5% sucrose
solution (MES-buffered saline with 250 mM Na2CO3). Gradients
were centrifuged for 17 h at 280,000 g (Beckman SW40Ti rotor)
at 4◦C. A total of 12 fractions (each 1 ml) were collected following
centrifugation.
Measurement of NO Metabolites
Quantification of nitrite and nitrate levels in myocardial
homogenates was achieved using a method outlined by Nussler
et al. (2006). Freshly prepared homogenates were ultra-filtrated
using Centrisart 1 columns with a molecular weight cut-off of
10 kDa (Sartorius #12329E). Nitrate pools from resulting ultra-
filtrates were converted to nitrite with nitrate reductase and
the total nitrite concentration of each sample was determined
using 2,3-diaminonapthalene, as described (Nussler et al.,
2006).
Reagent Supplies
All reagents were from Sigma Aldrich unless otherwise stated.
Antibodies used for Western blotting: Cav1 #610406 (1:5000),
Cav 3 #610420 (1:5000), eNOS #610296 (1:1000), phospho-
Ser1177- eNOS # 612392 (1:1000) (BD Biosciences), troponin
I (TnI) #4002 (1:1000), Ser23,24 phospho-TnI #4004 (1:1000),
VASP #3112 (1:1000), Ser239 phospho-VASP #3114 (1:1000) (Cell
Signalling Technology), and GAPDH #G9545 (1:50000) (Sigma).
Statistics
Results are expressed as mean ± SEM of n (cells) and
N (animals/patients) observations. Statistical analysis was
performed using the Student’s t-test.
RESULTS
In order to select a clinically relevant simvastatin dose, we
considered serum levels of the drug and its IC50; a daily dose
of simvastatin (40 mg/kg) was used to give peak plasma levels
between 5 and 10 times the IC50 in the rat (see Germershausen
et al., 1989; Masters et al., 1995). This is higher than the dose used
in man (up to 80 mg daily; i.e., 1.1 mg/kg for a 70 kg patient)
because the hepatic activity of HMG CoA reductase has been
estimated to be up to 10 times higher in rat than man (Dansette
et al., 2000). Animals were treated with statins for 2 weeks to
allow sufficient time for compensatory changes in elements of the
cholesterol homeostasis pathways to occur.
Simvastatin Treatment in the Rat
Selectively Increases Ventricular
Myocyte Lusitropy
We began by looking at the consequences of statin treatment
for isolated ventricular myocyte function (Figure 1). Simvastatin
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FIGURE 1 | The effect of simvastatin treatment on [Ca2+]i transient and shortening. (A) Representative traces and scatter plots of amplitude and kinetics of
the [Ca2+]i transient. Transient amplitude is expressed as % change in fura-2 ratio units (RU) over baseline. There was no difference in diastolic [Ca2+]i between
groups (0.967 ± 0.008 vs. 0.976 ± 0.003 RU in cells from control and statin-treated animals respectively). n = 34–35 cells from 7 to 8 animals per group.
(B) Representative traces and scatter plot of amplitude and kinetics of shortening. Shortening amplitude is expressed as % of resting cell length. There was no
difference in resting cell length between groups (110 ± 2 vs. 110 ± 2 µm in cells from control and statin-treated animals respectively). Plots show mean ± SEM from
n = 34–48 myocytes from 7 to 8 animals per group. ∗∗∗P < 0.001 vs. control group, Student’s t-test.
had no effect on the amplitude of the [Ca2+]i transient or
shortening. The rate of decay of the [Ca2+]i transient was
similar in cells from statin treated animals and controls,
however, there was a marked hastening of the rate of
relaxation (P < 0.001) with statin treatment, as indexed
by the time to half (t0.5) relaxation (0.108 ± 0.005 vs.
0.144± 0.006 s; n= 48/34 cells, N = 8/7 animals in statin/control
groups).
Simvastatin Treatment Increases
Phosphorylation of Troponin I
Increased lusitropy in the absence of a corresponding change
in [Ca2+]i transient decay is consistent with increased
phosphorylation of TnI which enhances the off-rate of Ca2+
from TnC (Zhang et al., 1995). Indeed, there was a 2.7-fold
increase in phosphorylation of TnI at Ser23/24 (P < 0.01) in
myocardium from statin-treated rats compared with controls
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FIGURE 2 | Simvastatin treatment increases phosphorylation of troponin I (TnI). Representative immunoblots (A) and scatter plots showing myocardial levels
of total troponin I (B) and Ser23/24 phosphorylated TnI (pTnI) (C) in control and statin-treated animals. Total TnI is normalized to GADPH, pTnI is normalized to total
TnI. Plots show mean ± SEM from N = 6 animals per group. ∗∗P < 0.01 vs. control group, Student’s t-test.
[0.62 ± 0.1 vs. 0.23 ± 0.03 arbitrary units (AUs); N = 6], in the
absence of a change in TnI expression (Figure 2).
Simvastatin Treatment and eNOS Activity
TnI is phosphorylated at Ser23/24 by both protein kinase (PK) A
and PKG, and PKG is a likely mediator of this phosphorylation
as its activity is stimulated by NO and NO bioavailability is
increased by in vitro statin treatment in both endothelial cells
and cardiac myocytes (Feron et al., 2001; Pugh et al., 2014).
Therefore, we next measured indices of NO production: eNOS
expression and phosphorylation, and NO metabolites. As shown
in Figure 3, simvastatin treatment increased the expression of
eNOS (4.15 ± 0.65 vs. 1.14 ± 0.17 AU; N = 6) and Ser1177-
phosphorylated eNOS (1.73 ± 0.29 vs. 0.62 ± 0.16 AU; N = 6),
although the proportion of total eNOS phosphorylated was
unchanged. There was a trend (P = 0.06) for an increase in
NO metabolites (nitrates and nitrites) with statin treatment
(1.85 ± 0.51 vs. 0.99 ± 0.19 AU; N = 5/6). In addition to
increased eNOS expression and phosphorylation, NO production
can be enhanced by reduced expression of caveolin (Cav), the
constitutive inhibitor of NOS. Acute in vitro statin treatment
reduces Cav3 expression in the adult cardiac myocyte (Pugh
et al., 2014). In the present study, chronic in vivo statin treatment
reduced myocardial expression of both the muscle-specific Cav3
(1.18 ± 0.14 vs. 2.02 ± 0.15 AU; N = 6) and the ubiquitously
expressed Cav1 (0.16 ± 0.01 vs. 0.25 ± 0.03 AU; N = 6)
(P < 0.05, see Figure 4), which would be predicted to enhance
eNOS activity. These are important findings because, although
SRE control of Cav1 is established (Bist et al., 1997), there is no
direct evidence of the same control for Cav3.
We were not able to index PKG activity directly due
to limitations of tissue supply (hearts were used for both
myocyte and myocardial homogenate preparations). Instead we
used an alternative means of assessing PKG activity through
measurement of phosphorylation of vasodilator stimulated
phosphoprotein (VASP) at Ser239, which is the site preferentially
targeted by PKG. This approach is commonly employed to assess
PKG activity in both myocyte and myocardial preparations (e.g.,
Sartoretto et al., 2009; van Heerebeek et al., 2012). As shown in
Figure 5, there was a trend for an increase in the ratio of Ser239-
phospho VASP:VASP in statin-treated samples (1.18 ± 0.15 vs.
0.99 ± 0.11 ratio units; N = 9) consistent with NO-dependent
stimulation of PKG.
Simvastatin Treatment and
Serum/Myocardial Cholesterol
Statin treatment over a 2 week period had no impact on
serum or cholesterol (Figure 6A) which is consistent with
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FIGURE 3 | Simvastatin increases eNOS expression and phosphorylation. Representative immunoblots (A) and scatter plots showing myocardial levels of
eNOS (B) and Ser1177 phosphorylated eNOS (p-eNOS, C) normalized to GAPDH. (D) The proportion of total eNOS phosphorylated at Ser1177 was not different
between groups. (E) NO metabolites (nitrate + nitrite) measured by a fluorimetric assay. Plots show mean ± SEM from N = 6 animals per group. ∗∗P < 0.01 vs.
control group, Student’s t-test.
other studies using normocholesterolemic rodents (Chen et al.,
2003; Whitehead et al., 2015). We have previously shown
reduced myocyte cholesterol levels in adult cardiac cells acutely
treated with simvastatin for 2 days in vitro, consistent with
reduced de novo myocyte cholesterol synthesis (Pugh et al.,
2014). However, with prolonged statin treatment, as used
in the present study, we would predict that SRE-dependent
changes in cholesterol homeostatic proteins, including Cav,
would act to return myocardial cholesterol to normal levels.
This prediction is supported by data showing no difference
in myocardial cholesterol between control and statin-treated
animals (Figure 6B). There was also no significant difference
in the distribution of cholesterol between membrane fractions
(Figure 6C).
Effect of Statin on β-AR Responsiveness
Acute cholesterol depletion of adult cardiac myocytes with
methyl-β-cyclodextrin (which displaces Cav3 from caveolar
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FIGURE 4 | Simvastatin reduces expression of caveolins 1 and 3. Representative immunoblots (A) and scatter plots showing myocardial expression of Cav1 α
(upper band) and β isoforms (B) and Cav3 (C). Plots show mean ± SEM from N = 6 animals per group. ∗P < 0.05, ∗∗P < 0.01 vs. control group, Student’s t-test.
FIGURE 5 | Effect of simvastatin on Ser239-phosphorylated VASP, an index of PKG activity. (A) Representative immunoblots showing
Ser239-phosphorylated VASP and VASP expression in rat ventricular myocytes ± 8-Bromo cGMP (200 µM for 15 min, as a positive control for PKG activity) and
myocardial homogenates from control and statin-treated animals. (B) Ratio of p-VASP to VASP. Plot shows mean ± SEM of N = 9 animals per group.
domains) has been shown to increase the sensitivity of β1-
adrenoceptor (AR) responses and to markedly enhance β2-
AR responsiveness (Agarwal et al., 2011; Macdougall et al.,
2012). Cardiac myocytes treated with simvastatin in vitro over
2 days show enhanced inotropic responses to β2-AR stimulation
(with no change in β1-AR responses), in association with
reduced levels of Cav3 and cholesterol (Pugh et al., 2014). An
important question is whether statin treatment for 2 weeks
in vivo, which reduces Cav1/3 expression without affecting
myocardial cholesterol, modulates β-AR responsiveness. There
was no significant effect of simvastatin treatment on the inotropic
or lusitropic response to β1- or β2-AR stimulation (see Figure 7).
However, statin treatment attenuated (P < 0.05) the increased
rate of [Ca2+]i transient decay (indexed by % change in t0.5
transient decay) which was seen with both β1-AR stimulation
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FIGURE 6 | Statin treatment for 2 weeks has no impact on serum or myocardial cholesterol levels. (A) Serum cholesterol expressed as a % change from
values on day 0 (N = 12–15 animals). (B) Myocardial cholesterol, normalized to myocardial total protein (N = 10 animals). (C) Myocardial cholesterol following
sucrose gradient fractionation, values are expressed as a % of total cholesterol across all fractions (N = 3 animals).
(−25 ± 2 vs. −33 ± 2%; n = 22/14 cells) and β2-AR stimulation
(−7.1± 1.1 vs.−13± 2%; n= 23/21 cells, N = 4/3 animals).
Are Observations Made in Rats
Reflective of the Human Population?
In order to establish whether observed changes in TnI, eNOS, and
Cav in our rodent model are of clinical relevance, we obtained
samples (n = 22) of human (atrial) myocardium from male
patients undergoing coronary artery bypass surgery, the majority
of whom were taking statins at the time of surgery. See Table 1
for patient data. There was no difference in age between control
and statin groups, and those with a diagnosis of diabetes were
excluded from the study (as diabetes has a myriad of cardiac
effects including changes in Cav expression) (Murfitt et al., 2015).
Key changes in protein expression/phosphorylation with statin
treatment in the rat were mirrored in human samples, although
possibly because of the small sample size these did not attain
statistical significance. Sample size is limited by human tissue
availability; it is particularly difficult to find patients undergoing
by-pass surgery who are not prescribed statins (limited to N = 6
in our study). Levels of phosphorylated TnI (as a proportion
of total TnI) were increased 2.2-fold (P = 0.2) with statin
treatment (1.52± 0.48 vs. 0.67± 0.13 AU; N = 14/6) (Figure 8).
Whilst eNOS levels were similar between groups, there was a
trend for an increase (P = 0.1) in phosphorylated eNOS in
the statin group (17.7 ± 1.7 vs. 13.3 ± 0.8 AU; N = 14/6).
Cav-1 levels were reduced by ≈50% (P = 0.1) in the statin-
treated group (1.07 ± 0.27 vs. 1.92 ± 0.54 AU; N = 14/6)
whereas Cav-3 expression was similar between groups (Figure 9).
Thus human data are in general agreement with our findings
from a rodent model that chronic statin treatment enhances TnI
phosphorylation which could be ascribed in part to enhanced
NOS activity.
DISCUSSION
Here, we show a pleiotropic effect of statin treatment that would
be of benefit to cardiac function. Simvastatin treatment increases
the rate of relaxation of the cardiac myocyte, consistent with
a NO-dependent modulation of TnI phosphorylation mediated
via PKG.
Basal Myocyte Function and β-AR
Responsiveness
We have previously shown that acute simvastatin treatment of
cardiac myocytes in vitro has lusitropic effects, but these were
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FIGURE 7 | Effect of statin treatment on the response to β-adrenoceptor (AR) stimulation. (A) Percentage change from baseline in amplitude/kinetics of the
[Ca2+]i transient and shortening in response to β1-AR stimulation with 100 nM isoprenaline in the presence of 100 nM ICI 118,551 (n = 14–22 cells from 3 to 4
animals per group). (B) Percentage change from baseline in amplitude/kinetics of the [Ca2+]i transient and shortening in response to β2-AR stimulation with 10 µM
zinterol in the presence of 300 nM CGP20712A (n = 23–28 cells from 4 animals per group). Plots show mean ± SEM. ∗P < 0.05 vs. saline-treated group, Student’s
t-test.
TABLE 1 | Details of male patients from which right atrial samples were
obtained.
Age Statin Dose (mg/day)
65 – –
74 – –
54 – –
30 – –
75 – –
65 – –
64 Atorvastatin 10
71 Simvastatin 20
60 Atorvastatin 20
79 Atorvastatin 20
68 Pravastatin 40
72 Atorvastatin 40
49 Rosuvastatin 10
69 Atorvastatin 40
71 Atorvastatin 40
55 Atorvastatin 80
72 Atorvastatin 80
50 Atorvastatin 80
65 Atorvastatin 80
68 Atorvastatin 80
All patients were undergoing coronary artery by-pass surgery. None had received a
diagnosis of diabetes. There was no difference in age between the control (61 ± 7,
n = 6) and statin-treated (65 ± 2, n = 14) groups (P > 0.05).
associated with corresponding changes in the [Ca2+]i transient
which suggests an alternative mechanism. A few studies have
examined the impact of chronic statin treatment in vivo on basal
cardiac function. In common with our own findings, these studies
report that statins have no impact on indices of contractility.
In the rat, a 2 week treatment with atorvastatin had no effect
on the magnitude of contraction in isolated atrial preparations
(Schmechel et al., 2009) and after 10 weeks, no alternations in
cardiac function (ejection fraction, maximum rate of pressure
change) were detected by echocardiography (Yao et al., 2009).
With reference to improved diastolic function, a 6 month
treatment with rosuvastatin has been shown to significantly
reduce the Tei index, a parameter which incorporates myocardial
relaxation time, in patients without evidence of coronary
artery disease (Talini et al., 2008). By contrast, other work
has shown that 70% of naïve patients without overt cardiac
dysfunction who were given atorvastatin for up to 6 months
developed worsening diastolic function (defined as a 10% change
in three echocardiographic indices of diastolic performance)
(Silver et al., 2004). In both these studies, individuals were
hypercholesterolemic, so the impact of statin treatment on serum
cholesterol must be considered.
Treatment of rats for 2 weeks with 40 mg/kg simvastatin has
no impact on the inotropic or lusitropic response of isolated
ventricular myocytes to stimulation of β1- and β2-ARs. However,
the fact that lusitropy is unchanged whilst [Ca2+]i transient
decay is slowed could suggest a minor potentiation of lusitropic
responses to β-AR with statin treatment (through enhanced
phosphorylation of TnI) which is masked by changes in the
[Ca2+]i transient. The lack of impact of statin treatment on
inotropic responses to β2-AR stimulation contrasts with the
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FIGURE 8 | Effect of statin treatment on TnI and Ser23/24 phosphorylated TnI (pTnI) in human myocardium. Representative immunoblots (A) and scatter
plots showing expression of total TnI normalized to GAPDH (B) and pTnI normalized to total TnI (C) in atrial muscle from statin-treated male patients (N = 14).
Patients not taking statins formed the control group (N = 6). SS = standard sample to allow inter-gel comparisons (see Materials and Methods, Western blotting).
Plots show mean ± SEM. ∗P < 0.05 vs. control group (Student’s t-test).
effect of in vitro statin treatment which markedly enhances this
(Pugh et al., 2014). We suggest that the ability of short-term
statin treatment to reduce myocyte cholesterol underlies its
impact on β2-AR stimulation, as its effects are mirrored by
acute cholesterol depletion of the cardiac cell with methyl β
cyclodextrin (Macdougall et al., 2012). Reduction in membrane
cholesterol may be essential to cause sufficient disruption of
the caveolar microdomain, which normally facilitates coupling
between the β2-AR and the inhibitory G protein, Gαi (see,
Macdougall et al., 2012). It is interesting to note that the ≈40%
loss of both Cav isoforms is not associated with major cardiac
dysfunction and, taken in the context of treatments which disrupt
the caveolar domain by cholesterol depletion or Cav knockout
(Galbiati et al., 2001), may suggest that the caveolae contain a
functional excess of Cav protein. Other data for effects of in vivo
statin treatment on β-AR responsiveness are sparse. A minor
decrease in the inotropic response of atrial preparations to non-
selective β-AR stimulation with isoprenaline has been reported in
rats treated for 2 weeks with atorvastatin (Schmechel et al., 2009).
NO Bioavailability
Our data suggest that statins have multiple effects which
contribute to elevated NO bioavailability. In the rat, statin
treatment increases the expression of myocardial eNOS and
phospho-eNOS and reduces expression of two of its inhibitory
mediators Cav1 and Cav3. These data accord with many
other reports in the literature of statins’ ability to increase
NO in various cells types. In the intact heart, the functional
relevance of increased NO with in vivo statin treatment has
been demonstrated. For example, in pigs treated for 5 days
with rosuvastatin, cardioprotective effects (reduced infarct size
and improved mechanical function after I-R) were absent when
a NOS inhibitor was administered concurrently with statins
(Bulhak et al., 2005). In this case, increased eNOS expression was
not responsible for enhanced NO bioavailability.
The source of enriched eNOS protein and NO production is
an important question. eNOS is expressed in endothelial cells
and cardiac myocytes, and both cell types are present in the
myocardial samples used for protein expression data presented
in Figure 3. The ability of statins to increase endothelial cell
NO bioavailability is well-established (Laufs et al., 1998; Kureishi
et al., 2000; Feron et al., 2001). However, as lusitropic effects of
statin treatment are observed in cardiac myocytes this suggests
that myocyte NO production is targeted by statins, as one might
predict that paracrine (endothelial) NO effects would not persist
in the isolated myocyte. This does not preclude a contribution
from endothelial cells in the intact heart; the functional effects we
have documented may well be underestimated if this is the case.
Caveolin Expression
Sterol regulatory element transcriptional control acts to preserve
cellular cholesterol levels following inhibition of de novo
cholesterol synthesis. Caveolae are sites of cholesterol eﬄux
(Fielding and Fielding, 1995). Recent data (from non-cardiac
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FIGURE 9 | Effect of statin treatment on proteins that regulate NO production in human myocardium. Representative immunoblots from the same gel and
scatter plots showing expression of eNOS and Ser1177 phosphorylated eNOS (p-eNOS) (A,B), Cav-1 and Cav-3 (C,D) in atrial muscle from statin-treated male
patients (N = 14). Male patients not taking statins formed the control group (N = 6). Plots show mean ± SEM.
cells) suggest that caveolin regulates cholesterol eﬄux to HDL
through direct interaction with the ATP binding cassette
transporter G1 (ABCG1) (Gu et al., 2014). SRE transcriptional
control of Cav1 has been established (Bist et al., 1997) suggesting
that caveolin is implicated in cellular cholesterol homeostasis.
Our data support the concept of SRE control of Cav1 and
Cav3 transcription. We saw a ≈40% reduction in expression of
both Cav isoforms in the statin group. Myocardial cholesterol
is unchanged at this time point, consistent with SRE-dependent
regulation of cellular cholesterol. Comparison with data from
in vitro statin treatment for 2 days (Pugh et al., 2014) supports
the concept that, whilst myocardial cholesterol initially falls with
statin treatment, it is normalized after >2 days, in part through
down-regulation of Cav which normally contributes to cellular
cholesterol eﬄux. Of note, most eNOS is immunoprecipitated by
antibodies to Cav1 in endothelial cells and by antibodies to Cav3
in cardiac myocytes (Feron et al., 1996). Thus our rodent data
are consistent with the view that eNOS activity is enhanced in
endothelial cells and myocytes by reductions in Cav1 and Cav3
expression respectively.
TnI Phosphorylation
In the cardiac myocyte, NO is the main activator of soluble
guanyl cyclase (sGC). The resulting elevation of cGMP has
several consequences, one of which is stimulation of protein
kinase G. Troponin I is a target of PKG in the cardiac myocyte
(Yuasa et al., 1999); its phosphorylation at Ser23/24 increases
the off-rate of Ca2+ from TnC and hastens relaxation. NO
donors and elevation of cGMP have similar effects on relaxation
rate in ferret papillary muscle (Smith et al., 1991). We did not
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detect any decrease in contraction amplitude in cells from
statin treated animals which might be predicted as a result
of decreased TnC Ca2+ affinity; this suggests some additional
compensatory effects of statins. Phospholamban is another
target of PKG, but the lack of increase in [Ca2+]i transient
amplitude or kinetics with statin treatment, suggests that
compartmentation of cGMP signaling limits the targets of
PKG in this case (see Castro et al., 2006). Of note, increased
myocardial cGMP has been linked with cardioprotective effects
during episodes of I-R (Bice et al., 2014) and PKG has
been proposed as one of the salvage kinases that protects
the heart from I-R damage (Burley et al., 2007). Support for
an inverse correlation between cholesterol and PKG activity
comes from data showing that rats fed a high cholesterol diet
have decreased myocardial activity of PKG, as assessed by
phosphorylation of TnI (Giricz et al., 2009), although in this study
the mechanism that links altered cholesterol with PKG activity
was not established.
Human Data
Human samples come from a heterogeneous population (in
terms of disease severity, medication, length of statin exposure,
etc.) and there is limited availability of ‘control’ samples as most
patients undergoing cardiac surgery will be taking these drugs.
This contrasts with the well-controlled experiments possible
using a rodent model. Despite the limitations of working with
human tissue, the fact that our data from these samples show
similarities to findings in rodent muscle (in terms of clear trends
for changes in phosphorylated TnI, phosphorylated eNOS and
Cav1) is persuasive.
A significant reduction in myocardial levels of TnI was
observed in samples from individuals taking statins which was
absent in the rodent model. Reduced myocardial TnI could be
explained by a loss of protein from damaged muscle, perhaps
because of more severe disease in this patient group; TnI loss
has been reported in a variety of cardiac diseases, including
post-infarction remodeling (Ricchiuti et al., 1997). If this is
the case, it should be noted that statins are prescribed to
those without established cardiac disease, therefore loss of TnI
would not be a universal finding in all who take these drugs.
Another possibility to explain TnI loss is statin-linked myopathy,
similar to that reported in skeletal muscle (Bruckert et al.,
2005), however, there are no reports of cardiac myopathy with
statin treatment (see, Bouitbir et al., 2011) and we also saw
no effect of statin treatment on total TnI expression in our
rodent model. Overall, the important finding from atria from
statin-treated individuals is a trend for an increase in the
proportion of TnI which is phosphorylated, consistent with data
in the rat.
Although eNOS expression was similar in control and statin
groups, there was a trend for increased eNOS phosphorylation
and reduced Cav1 expression in the statin-treated group.
This correlates well with established sensitivity of mechanisms
of altered NO production in other tissues. In endothelial
cells it is Akt-dependent eNOS phosphorylation and Cav1
expression that are most sensitive to statins effects (Feron
et al., 2001; Urbich et al., 2002). For example, reduced Cav 1
abundance is observed at 1000 times lower concentrations
of atorvastatin than promoted increased eNOS expression.
This suggests that phosphorylation of eNOS and depletion
of Cav are likely to be the main mechanisms for statin-
induced alterations in NO in vivo. Of note, if control of
endothelial and cardiac myocyte eNOS in the rat heart is
mirrored in the human heart, this implies that the primary Cav
dependent impact of statin treatment could be on endothelial
cell NO production, but this is likely to have paracrine
influences on the myocyte in situ via PKG activation and TnI
phosphorylation.
CONCLUSION
We have shown for the first time that statin treatment
in vivo has effects on cardiac myocyte relaxation, which are
associated with changes which increase NO bioavailability
and phosphorylation of the myofilament protein TnI. One
limitation of the work is that it only shows association between
aspects of contractile function, proteins which control NO
production and TnI phosphorylation. Cause and effect has
not been directly established. However, available literature for
statin effects on NO, and NO effects on TnI phosphorylation
provide strong support for the concept. These data suggest
that autocrine and paracine effects of NO released within the
myocardium will improve cardiac filling per se. Furthermore,
the role of NO in cardioprotection suggests that this effect
would have other benefits during times of cardiac stress
(I-R). These data support the concept of an additional
pleiotropic action of statins that improves cardiac function and
cardioprotection even in individuals without established cardiac
disease.
AUTHOR CONTRIBUTIONS
DM, SP designed work, acquired and analyzed and interpreted
data, critically revised manuscript, approved final version, are
accountable for all aspects of the work; HB, SL acquired and
analyzed data, helped draft and revise manuscript, approved
final version, are accountable for all aspects of the work; KP
designed work, interpreted data, critically revised manuscript,
approved final version, is accountable for all aspects of the
work; SC conceived and designed work, interpreted data, wrote
manuscript, approved final version, is accountable for all aspects
of the work.
FUNDING
This work was funded by the British Heart Foundation
(PG/09/051/27828).
Frontiers in Pharmacology | www.frontiersin.org 12 April 2017 | Volume 8 | Article 203
fphar-08-00203 April 13, 2017 Time: 15:20 # 13
MacDougall et al. Statins Promote Cardiac Lusitropy
REFERENCES
Agarwal, S. R., Macdougall, D. A., Tyser, R., Pugh, S. D., Calaghan, S. C., and
Harvey, R. D. (2011). Effects of cholesterol depletion on compartmentalized
cAMP responses in adult cardiac myocytes. J. Mol. Cell Cardiol. 50, 500–509.
doi: 10.1016/j.yjmcc.2010.11.015
Bauersachs, J., Galuppo, P., Fraccarollo, D., Christ, M., and Ertl, G.
(2001). Improvement of left ventricular remodeling and function by
hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin
in rats with heart failure after myocardial infarction. Circulation 104, 982–985.
doi: 10.1161/hc3401.095946
Baytan, S. H., Alkanat, M., Okuyan, M., Ekinci, M., Gedikli, E., Ozeren, M., et al.
(2008). Simvastatin impairs spatial memory in rats at a specific dose level.
Tohoku J. Exp. Med. 214, 341–349. doi: 10.1620/tjem.214.341
Bice, J. S., Burley, D. S., and Baxter, G. F. (2014). Novel approaches and
opportunities for cardioprotective signaling through 3′,5′-cyclic guanosine
monophosphate manipulation. J. Cardiovasc. Pharmacol. Ther. 19, 269–282.
doi: 10.1177/1074248413518971
Bist, A., Fielding, P. E., and Fielding, C. J. (1997). Two sterol regulatory element-
like sequences mediate up-regulation of caveolin gene transcription in response
to low density lipoprotein free cholesterol. Proc. Natl. Acad. Sci. U.S.A 94,
10693–10698. doi: 10.1073/pnas.94.20.10693
Bouitbir, J., Charles, A. L., Echaniz-Laguna, A., Kindo, M., Daussin, F., Auwerx, J.,
et al. (2011). Opposite effects of statins on mitochondria of cardiac and skeletal
muscles: a ’mitohormesis’ mechanism involving reactive oxygen species and
PGC-1. Eur. Heart J. 33, 1397–1407. doi: 10.1093/eurheartj/ehr224
Bruckert, E., Hayem, G., Dejager, S., Yau, C., and Begaud, B. (2005).
Mild to moderate muscular symptoms with high-dosage statin therapy
in hyperlipidemic patients–the PRIMO study. Cardiovasc. Drugs Ther. 19,
403–414. doi: 10.1007/s10557-005-5686-z
Burley D. S., Hamid S. A., and Baxter G. F. (2007). Cardioprotective actions of
peptide hormones in myocardia lischemia. Heart Fail. Rev. 12, 279–291. doi:
10.1007/s10741-007-9029-y
Bulhak, A. A., Gourine, A. V., Gonon, A. T., Sjoquist, P. O., Valen, G., and
Pernow, J. (2005). Oral pre-treatment with rosuvastatin protects porcine
myocardium from ischaemia/reperfusion injury via a mechanism related to
nitric oxide but not to serum cholesterol level. Acta Physiol. Scand. 183,
151–159. doi: 10.1111/j.1365-201X.2004.01392.x
Calaghan, S., Kozera, L., and White, E. (2008). Compartmentalisation of cAMP-
dependent signalling by caveolae in the adult cardiac myocyte. J. Mol. Cell
Cardiol. 45, 88–92. doi: 10.1016/j.yjmcc.2008.04.004
Calaghan, S. C., White, E., and Colyer, J. (1998). Co-ordinated changes in
cAMP, phosphorylated phospholamban, Ca2+ and contraction following beta-
adrenergic stimulation of rat heart. Pflugers Arch. 436, 948–956. doi: 10.1007/
s004240050728
Castro, L. R., Verde, I., Cooper, D. M., and Fischmeister, R. (2006). Cyclic
guanosine monophosphate compartmentation in rat cardiac myocytes.
Circulation 113, 2221–2228. doi: 10.1161/CIRCULATIONAHA.105.599241
Chan, P. S., Nallamothu, B. K., Gurm, H. S., Hayward, R. A., and Vijan, S.
(2007). Incremental benefit and cost-effectiveness of high-dose statin therapy
in high-risk patients with coronary artery disease. Circulation 115, 2398–2409.
doi: 10.1161/CIRCULATIONAHA.106.667683
Chen, J., Nagasawa, Y., Zhu, B. M., Ohmori, M., Harada, K., Fujimura, A.,
et al. (2003). Pravastatin prevents arrhythmias induced by coronary artery
ischemia/reperfusion in anesthetized normocholesterolemic rats. J. Pharmacol.
Sci. 93, 87–94. doi: 10.1254/jphs.93.87
Dansette, P. M., Jaoen, M., and Pons, C. (2000). HMG-CoA reductase activity
in human liver microsomes: comparative inhibition by statins. Exp. Toxicol.
Pathol. 52, 145–148. doi: 10.1016/S0940-2993(00)80107-4
Davignon, J. (2004). Beneficial cardiovascular pleiotropic effects of statins.
Circulation 109, III39–III43. doi: 10.1161/01.CIR.0000131517.20177.5a
Delbosc, S., Cristol, J. P., Descomps, B., Mimran, A., and Jover, B. (2002).
Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative
stress. Hypertension 40, 142–147. doi: 10.1161/01.HYP.0000024348.87637.6F
Di Napoli, P. D., Taccardi, A. A., Grilli, A., De Lutiis, M. A., Barsotti, A., Felaco, M.,
et al. (2005). Chronic treatment with rosuvastatin modulates nitric oxide
synthase expression and reduces ischemia-reperfusion injury in rat hearts.
Cardiovasc. Res. 66, 462–471. doi: 10.1016/j.cardiores.2005.02.008
Easom, R. A., and Zammit, V. A. (1984). Diurnal changes in the fraction
of 3-hydroxy-3-methylglutaryl-CoA reductase in the active form in rat
liver microsomal fractions. Biochem. J. 220, 739–745. doi: 10.1042/bj220
0739
Feron, O., Belhassen, L., Kobzik, L., Smith, T. W., Kelly, R. A., and Michel, T.
(1996). Endothelial nitric oxide synthase targeting to caveolae. Specific
interactions with caveolin isoforms in cardiac myocytes and endothelial cells.
J. Biol. Chem. 271, 22810–22814. doi: 10.1074/jbc.271.37.22810
Feron, O., Dessy, C., Desager, J. P., and Balligand, J. L. (2001). Hydroxy-
methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric
oxide synthase activation through a decrease in caveolin abundance. Circulation
103, 113–118. doi: 10.1161/01.CIR.103.1.113
Fielding, P. E., and Fielding, C. J. (1995). Plasma membrane caveolae mediate the
eﬄux of cellular free cholesterol. Biochemistry 34, 14288–14292. doi: 10.1021/
bi00044a004
Galbiati, F., Engelman, J. A., Volonte, D., Zhang, X. L., Minetti, C., Li, M.,
et al. (2001). Caveolin-3 null mice show a loss of caveolae, changes in
the microdomain distribution of the dystrophin-glycoprotein complex, and
t-tubule abnormalities. J. Biol. Chem. 276, 21425–21433. doi: 10.1074/jbc.
M100828200
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S.,
et al. (2012). Pharmacological actions of statins: a critical appraisal in the
management of cancer. Pharmacol. Rev. 64, 102–146. doi: 10.1124/pr.111.
004994
Germershausen, J. I., Hunt, V. M., Bostedor, R. G., Bailey, P. J., Karkas, J. D.,
and Alberts, A. W. (1989). Tissue selectivity of the cholesterol-lowering agents
lovastatin, simvastatin and pravastatin in rats in vivo. Biochem. Biophys. Res.
Commun. 158, 667–675. doi: 10.1016/0006-291X(89)92773-3
Giricz, Z., Gorbe, A., Pipis, J., Burley, D. S., Ferdinandy, P., and Baxter,
G. F. (2009). Hyperlipidaemia induced by a high-cholesterol diet leads
to the deterioration of guanosine-3′,5′-cyclic monophosphate/protein kinase
G-dependent cardioprotection in rats. Br. J. Pharmacol. 158, 1495–1502.
doi: 10.1111/j.1476-5381.2009.00424.x
Goldstein, J. L., and Brown, M. S. (1990). Regulation of the mevalonate pathway.
Nature 343, 425–430. doi: 10.1038/343425a0
Gu, H. M., Wang, F. Q., and Zhang, D. W. (2014). Caveolin-1 interacts with
ATP binding cassette transporter G1 (ABCG1) and regulates ABCG1-mediated
cholesterol eﬄux. Biochim. Biophys. Acta 1841, 847–858. doi: 10.1016/j.bbalip.
2014.02.002
Ikonen, E., and Parton, R. G. (2000). Caveolins and cellular cholesterol balance.
Traffic 1, 212–217. doi: 10.1034/j.1600-0854.2000.010303.x
Kureishi, Y., Luo, Z., Shiojima, I., Bialik, A., Fulton, D., Lefer, D. J., et al. (2000).
The HMG-CoA reductase inhibitor simvastatin activates the protein kinase
Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med.
6, 1004–1010. doi: 10.1038/79510
Laufs, U., La Fata, V., Plutzky, J., and Liao, J. K. (1998). Upregulation of endothelial
nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97,
1129–1135. doi: 10.1161/01.CIR.97.12.1129
Laufs, U., and Liao, J. K. (1998). Post-transcriptional regulation of endothelial
nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273,
24266–24271. doi: 10.1074/jbc.273.37.24266
Macdougall, D. A., Agarwal, S. R., Stopford, E. A., Chu, H., Collins, J. A., Longster,
A. L., et al. (2012). Caveolae compartmentalise beta2-adrenoceptor signals
by curtailing cAMP production and maintaining phosphatase activity in the
sarcoplasmic reticulum of the adult ventricular myocyte. J. Mol. Cell Cardiol.
52, 388–400. doi: 10.1016/j.yjmcc.2011.06.014
Macdougall, D. A., and Calaghan, S. (2013). A novel approach to the Langendorff
technique: preparation of isolated cardiomyocytes and myocardial samples
from the same rat heart. Exp. Physiol. 98, 1295–1300. doi: 10.1113/expphysiol.
2013.072827
Masters, B. A., Palmoski, M. J., Flint, O. P., Gregg, R. E., Wang-Iverson, D., and
Durham, S. K. (1995). In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin,
using neonatal rat skeletal myocytes. Toxicol. Appl. Pharmacol. 131, 163–174.
doi: 10.1006/taap.1995.1058
Murfitt, L., Whiteley, G., Iqbal, M. M., and Kitmitto, A. (2015). Targeting caveolin-
3 for the treatment of diabetic cardiomyopathy. Pharmacol. Ther. 151, 50–71.
doi: 10.1016/j.pharmthera.2015.03.002
Frontiers in Pharmacology | www.frontiersin.org 13 April 2017 | Volume 8 | Article 203
fphar-08-00203 April 13, 2017 Time: 15:20 # 14
MacDougall et al. Statins Promote Cardiac Lusitropy
Nakagami, H., Jensen, K. S., and Liao, J. K. (2003). A novel pleiotropic effect
of statins: prevention of cardiac hypertrophy by cholesterol-independent
mechanisms. Ann. Med. 35, 398–403. doi: 10.1080/07853890310001294
Nussler, A. K., Glanemann, M., Schirmeier, A., Liu, L., and Nussler, N. C. (2006).
Fluorometric measurement of nitrite/nitrate by 2,3-diaminonaphthalene. Nat.
Protoc. 1, 2223–2226. doi: 10.1038/nprot.2006.341
Okuyama, H., Langsjoen, P. H., Hamazaki, T., Ogushi, Y., Hama, R., Kobayashi, T.,
et al. (2015). Statins stimulate atherosclerosis and heart failure: pharmacological
mechanisms. Expert. Rev. Clin. Pharmacol. 8, 189–199. doi: 10.1586/17512433.
2015.1011125
Pencina, M. J., Navar-Boggan, A. M., D’Agostino, RB Sr, Williams, K., Neely, B.,
Sniderman, A. D., et al. (2014). Application of new cholesterol guidelines to
a population-based sample. N. Engl. J. Med 370, 1422–1431. doi: 10.1056/
NEJMoa1315665
Pugh, S. D., Macdougall, D. A., Agarwal, S. R., Harvey, R. D., Porter, K. E.,
and Calaghan, S. (2014). Caveolin contributes to the modulation of basal and
beta-adrenoceptor stimulated function of the adult rat ventricular myocyte
by simvastatin: a novel pleiotropic effect. PLoS ONE 9:e106905. doi: 10.1371/
journal.pone.0106905
Reboulleau, A., Robert, V., Vedie, B., Doublet, A., Grynberg, A., Paul, J. L.,
et al. (2012). Involvement of cholesterol eﬄux pathway in the control of
cardiomyocytes cholesterol homeostasis. J. Mol. Cell Cardiol. 53, 196–205.
doi: 10.1016/j.yjmcc.2012.05.015
Renno, A. L., Alves-Junior, M. J., Rocha, R. M., De Souza, P. C., de Souza,
V. B., Jampietro, J., et al. (2015). Decreased expression of stem cell markers
by simvastatin in 7,12-dimethylbenz(a)anthracene (DMBA)-induced breast
cancer. Toxicol. Pathol. 43, 400–410. doi: 10.1177/0192623314544707
Ricchiuti, V., Zhang, J., and Apple, F. S. (1997). Cardiac troponin I and T
alterations in hearts with severe left ventricular remodeling. Clin. Chem. 43,
990–995.
Sartoretto, J. L., Jin, B. Y., Bauer, M., Gertler, F. B., Liao, R., and Michel, T.
(2009). Regulation of VASP phosphorylation in cardiac myocytes: differential
regulation by cyclic nucleotides and modulation of protein expression in
diabetic and hypertrophic heart. Am. J. Physiol. Heart Circ. Physiol. 297,
H1697–H1710. doi: 10.1152/ajpheart.00595.2009
Schmechel, A., Grimm, M., El-Armouche, A., Hoppner, G., Schwoerer, A. P.,
Ehmke, H., et al. (2009). Treatment with atorvastatin partially protects the
rat heart from harmful catecholamine effects. Cardiovasc. Res. 82, 100–106.
doi: 10.1093/cvr/cvp005
Silver, M. A., Langsjoen, P. H., Szabo, S., Patil, H., and Zelinger, A. (2004). Effect of
atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to
reverse that dysfunction. Am. J Cardiol. 94, 1306–1310. doi: 10.1016/j.amjcard.
2004.07.121
Smith, J. A., Shah, A. M., and Lewis, M. J. (1991). Factors released from
endocardium of the ferret and pig modulate myocardial contraction. J. Physiol.
439, 1–14. doi: 10.1113/jphysiol.1991.sp018653
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B.,
Eckel, R. H., et al. (2014). 2013 ACC/AHA guideline on the treatment of blood
cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of
the American college of cardiology/American heart association task force on
practice guidelines. J. Am. Coll. Cardiol. 63, 2889–2934. doi: 10.1016/j.jacc.2013.
11.002
Talini, E., DiBello, V., Bianchi, C., Palagi, C., le Donne, M. G., Penno, G., et al.
(2008). Early impairment of left ventricular function in hypercholesterolemia
and its reversibility after short term treatment with rosuvastatin A
preliminary echocardiographic study. Atherosclerosis 197, 346–354.
doi: 10.1016/j.atherosclerosis.2007.05.024
Urbich, C., Dernbach, E., Zeiher, A. M., and Dimmeler, S. (2002). Double-edged
role of statins in angiogenesis signaling. Circ. Res. 90, 737–744. doi: 10.1161/01.
RES.0000014081.30867.F8
van Heerebeek, L., Hamdani, N., Falcao-Pires, I., Leite-Moreira, A. F., Begieneman,
M. P., Bronzwaer, J. G., et al. (2012). Low myocardial protein kinase G activity
in heart failure with preserved ejection fraction. Circulation 126, 830–839.
doi: 10.1161/CIRCULATIONAHA.111.076075
Verma, S., Rao, V., Weisel, R. D., Li, S. H., Fedak, P. W., Miriuka, S., et al.
(2004). Novel cardioprotective effects of pravastatin in human ventricular
cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of
statins independent of endothelial cells. J. Surg. Res. 119, 66–71. doi: 10.1016/j.
jss.2003.10.011
Whitehead, N. P., Kim, M. J., Bible, K. L., Adams, M. E., and Froehner, S. C. (2015).
A new therapeutic effect of simvastatin revealed by functional improvement
in muscular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 112, 12864–12869.
doi: 10.1073/pnas.1509536112
Yao, L., Chen, G. P., Lu, X., Zheng, L. R., Mou, Y., and Hu, S. J. (2009). Effects
of atorvastatin on calcium-regulating proteins: a possible mechanism to repair
cardiac dysfunction in spontaneously hypertensive rats. Basic Res. Cardiol. 104,
258–268. doi: 10.1007/s00395-008-0751-y
Ye, Y., Martinez, J. D., Perez-Polo, R. J., Lin, Y., Uretsky, B. F., and Birnbaum, Y.
(2008). The role of eNOS, iNOS, and NF-kappaB in upregulation and
activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am.
J. Physiol. Heart Circ. Physiol. 295, H343–H351. doi: 10.1152/ajpheart.01350.
2007
Yuasa, K., Michibata, H., Omori, K., and Yanaka, N. (1999). A novel interaction
of cGMP-dependent protein kinase I with troponin T. J. Biol. Chem. 274,
37429–37434. doi: 10.1074/jbc.274.52.37429
Zhang, R., Zhao, J., Mandveno, A., and Potter, J. D. (1995). Cardiac troponin I
phosphorylation increases the rate of cardiac muscle relaxation. Circ. Res. 76,
1028–1035. doi: 10.1161/01.RES.76.6.1028
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The reviewer GV and handling Editor declared their shared affiliation, and the
handling Editor states that the process nevertheless met the standards of a fair and
objective review.
Copyright © 2017 MacDougall, Pugh, Bassi, Lotteau, Porter and Calaghan. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Pharmacology | www.frontiersin.org 14 April 2017 | Volume 8 | Article 203
